01—Abstract
Summary
Summary of the 10-Q filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. reported net income attributable to Humana of $545 milliona, or $4.51 per diluted common share, for the three months ended June 30, 2025, compared with $679 million, or $5.62 per diluted share, in the 2024 quarter.
For the six months ended June 30, 2025, net income attributable to Humana was $1.789 billionb, or $14.81 per diluted share, versus $1.420 billion, or $11.74 per diluted share, a year earlier. The filing states that these comparisons were significantly affected by put/call valuation adjustments on non-consolidating minority interest investments ($200 million in the quarter, $363 million for the six months), a $32 million impairment of indefinite-lived intangible assets, and $29 million and $53 million of value creation initiative charges for the quarter and six months, respectively. Total revenues rose 9.6% in the quarter to $32.39 billion, driven by premiums revenue of $30.72 billion, while the consolidated benefit ratio increased to 89.7% from 89.0%.
Balance sheet and liquidity: cash and cash equivalents rose to $4.04 billionc at June 30, 2025 from $2.22 billion at year-end 2024, and operating cash flow for the six months was $1.60 billion. Long-term debt increased to $12.59 billion, following the March 2025 issuance of $1.5 billion in net proceeds from new senior notes that repaid $577 million of notes maturing April 1, 2025. The company repurchased $100 million of common stock in the six months and had a remaining authorization of $2.8 billion as of July 29, 2025.
The filing states that the company's debt-to-capitalization ratio was 40.7% against a 60% covenant under its $5.0 billiond revolving credit agreement, which had no borrowings outstanding at June 30, 2025. The filing also discloses material legal and regulatory exposure. It describes CMS's Final RADV Rule, which eliminates the FFS Adjuster and plans extrapolated audit recoveries beginning with payment year 2018, with the company stating these matters could have a material adverse effect.
Humana also reports a pending lawsuit over the 2025 Star Ratings, refiled July 21, 2025, a securities class action, a derivative action, and a qui tam complaint in which DOJ partially intervened on May 1, 2025. The company states that it cannot estimate a loss beyond amounts already accrued.
02—Key points
Key Highlights
- Net income attributable to Humana was $545 million ($4.51 diluted EPS) in Q2 2025, down from $679 million ($5.62) in Q2 2024; six-month net income was $1.789 billion ($14.81) versus $1.420 billion ($11.74).
- Put/call valuation adjustments on non-consolidating minority interest investments were $200 million in Q2 2025 and $363 million for the six months, reported within other expense, net; the filing says these items significantly affected earnings comparisons.
- Total revenues were $32.39 billion for Q2 2025, up 9.6% from $29.54 billion, with premiums revenue of $30.72 billion, up 9.1%, mainly from higher per member Medicare premiums tied to an increased direct subsidy under the IRA.
- The consolidated benefit ratio rose to 89.7% in Q2 2025 from 89.0%, primarily reflecting business mix shifts toward state-based contracts and stand-alone PDP, plus a reduction in individual Medicare Advantage membership.
- Individual Medicare Advantage membership fell 388,300 members (6.9%) year over year to 5,229,300, inclusive of plan and county exits, while Medicare stand-alone PDP membership rose 3.7% and state-based contracts rose 13.7%.
- Cash and cash equivalents increased to $4.04 billion from $2.22 billion at year-end 2024; the company issued $1.48 billion in net proceeds of senior notes in March 2025 and repurchased $100 million of common stock in the six months.
- The filing describes a material pending regulatory matter: CMS's Final RADV Rule eliminates the FFS Adjuster and plans extrapolated recoveries beginning with PY 2018, which the company says could have a material adverse effect on results, financial position, or cash flows.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 30, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $32.39B$29.54B | +9.6% |
| SG&A Expenses | $3.55B$3.15B | +12.7% |
| Operating Income | $1.10B$1.14B | −3.8% |
| Net Income | $545.00M$679.00M | −19.7% |
| EPS (Basic) | $4.52$5.63 | −19.7% |
| EPS (Diluted) | $4.51$5.62 | −19.8% |
| Shares Outstanding (Basic) | 120.54M120.44M | +0.1% |
| Shares Outstanding (Diluted) | 120.75M120.67M | +0.1% |
05—Questions
Frequently Asked Questions
What drove the decline in Humana's second-quarter 2025 earnings per share?
Diluted EPS fell to $4.51 from $5.62 in the 2024 quarter. The filing attributes the comparison to put/call valuation adjustments on non-consolidating minority interest investments ($200 million in Q2 2025 versus $68 million in Q2 2024), a $32 million impairment of indefinite-lived intangible assets, and higher benefit and operating cost ratios. Income from operations decreased 3.8% to $1.10 billion.
How did Humana's revenue and membership trends look in the quarter?
Total revenues increased 9.6% to $32.39 billion. Total medical membership fell 9.0% year over year to 14.84 million, driven mainly by a 1.37 million decline in military services members and a 388,300 decline in individual Medicare Advantage members, partly offset by growth in state-based contracts and stand-alone PDP.
What is Humana's financial position and debt profile at June 30, 2025?
Total assets were $50.36 billion and total equity was $18.30 billion. Long-term debt was $12.59 billion, with no short-term debt outstanding, compared with $577 million of short-term notes at year-end 2024. The company states its debt-to-capitalization ratio was 40.7% against a 60% covenant, and it had $4.985 billion of remaining capacity under its revolving credit agreement.
What are the main legal and regulatory risks disclosed in this filing?
The filing discloses CMS's Final RADV Rule, which eliminates the FFS Adjuster and extrapolates audit results beginning with PY 2018, and Humana's lawsuit challenging it. It also describes a suit over the 2025 Star Ratings, refiled July 21, 2025, a securities class action and related derivative actions, and a False Claims Act complaint in which DOJ partially intervened on May 1, 2025. The company states that it cannot predict the outcomes or estimate losses beyond accrued amounts, and that outcomes could have a material adverse effect.
How much cash is the company returning to shareholders, and what is left under the buyback program?
In the six months ended June 30, 2025, Humana repurchased shares for $100 million and paid dividends of $214 million. Dividends were $0.8850 per share per quarter. The remaining repurchase authorization was $2.8 billion as of July 29, 2025.
06—Continue